Cytosorbents Crp
$ 0.49
1.88%
03 Jun - close price
- Market Cap 30,706,600 USD
- Current Price $ 0.49
- High / Low $ 0.52 / 0.45
- Stock P/E N/A
- Book Value 0.04
- EPS -0.19
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -1.42 %
- 52 Week High 1.39
- 52 Week Low 0.44
About
Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.
Analyst Target Price
$2.88
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-25 | 2025-11-13 | 2025-08-07 | 2025-05-14 | 2025-03-31 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-14 | 2023-11-09 | 2023-08-01 |
| Reported EPS | -0.08 | -0.09 | -0.05 | 0.03 | -0.02 | -0.14 | -0.08 | -0.08 | -0.12 | -0.13 | -0.21 | -0.14 |
| Estimated EPS | -0.05 | -0.0441 | -0.05 | -0.06 | -0.07 | -0.0533 | -0.06 | -0.1 | -0.12 | -0.14 | -0.12 | -0.14 |
| Surprise | -0.03 | -0.0459 | 0 | 0.09 | 0.05 | -0.0867 | -0.02 | 0.02 | 0 | 0.01 | -0.09 | 0 |
| Surprise Percentage | -60% | -104.0816% | 0% | 150% | 71.4286% | -162.6642% | -33.3333% | 20% | 0% | 7.1429% | -75% | 0% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CTSO
2026-06-01 00:51:48
CytoSorbents Corp (CTSO) shares on Nasdaq are trading at a low nominal level of USD 0.49, despite several Wall Street analysts maintaining significantly higher 12-month price targets, with a consensus of USD 5.38. The company, focused on blood purification therapies, continues to draw attention due to this disparity between its current market price and analyst expectations. However, a "hold" consensus rating and a wide range of targets from a small group of covering analysts highlight ongoing uncertainty regarding the company's execution and financial profile.
2026-05-29 01:39:16
CytoSorbents Corp (CTSO) shares on the Nasdaq Capital Market continue to trade at low single-digit levels, attracting risk-tolerant investors interested in medical technology stocks. The company, which focuses on blood purification technologies, is currently assessed using revenue-based metrics and enterprise-value-to-sales multiples due to its ongoing growth and commercialization phase and historical net losses. Market participants are closely watching for potential catalysts, including financial results, clinical, or regulatory updates.
2026-05-20 23:10:47
Cytosorbents' Q1 2026 earnings call revealed a combination of cautious optimism and ongoing challenges. The company reported modest revenue growth, driven by international sales outside Germany, alongside strong margins. However, it also faced headwinds from FX losses, regulatory delays in the U.S., and tight liquidity, leading to an increased GAAP net loss even as adjusted profitability improved due to cost controls.
2026-05-20 05:40:24
Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, showing modest growth despite currency headwinds and German market weakness. The company emphasized strong international direct sales, disciplined cost control, and progress toward operating cash flow breakeven by late 2026, even as U.S. regulatory approval for DrugSorb-ATR faces delays. Liquidity remains a concern due to a declining cash balance.
2026-05-19 11:39:00
CytoSorbents Corporation (CTSO) reported a larger-than-expected loss and missed revenue forecasts for Q1 2026, leading to a significant stock price decline. The company is pursuing regulatory approval for its DrugSorb-ATR device, which reduces bleeding risks during cardiac surgery, and is focused on cost reduction initiatives to achieve operating cash flow breakeven in the second half of 2026. Geopolitical disruptions in the Middle East impacted sales, but the company remains optimistic about its long-term growth and market expansion.
2026-05-15 12:39:56
Cytosorbents Corporation reported its Q1 2026 earnings, with revenues growing 2% year-over-year to $8.9 million, despite geopolitical headwinds in the Middle East. The company is actively pursuing FDA approval for its DrugSorb-ATR device for both ticagrelor and direct oral anticoagulant (DOAC) removal in cardiac surgery, with a dual pathway strategy. Cytosorbents aims to achieve operating cash flow breakeven in the second half of 2026 by optimizing efficiencies and a more focused sales approach, particularly in Germany.
